Abstract

Purpose of Review

The objective of this manuscript is to examine the current literature on the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD), its correlation with cardiovascular disease (CVD) outcomes, as well as to evaluate the update in nomenclature from non-alcoholic liver disease (NAFLD).

Recent Findings

The update of diagnostic criteria from NAFLD to MASLD reduces the stigma associated with alcohol consumption and poor health choices. It also shines a light on the crucial role of cardiometabolic risk factors in disease pathophysiology. The incidence and prevalence of MASLD are projected to increase significantly in the future as the population burden of cardiometabolic risk factors rises. MASLD is also a potent risk factor for developing CVD that should be tackled by using a multi-disciplinary team with a holistic approach.

Summary

As the new nomenclature for metabolic liver disease is adopted on a global scale, more research is needed to investigate the applicability of findings from previous trials focusing on NAFLD. It is anticipated that the epidemic of MASLD will continue to increase globally, hence the urgent need for therapeutic approaches to reverse this trend.

中文翻译：

---

代谢性脂肪肝的全球流行

摘要

审查目的

本手稿的目的是检查有关代谢功能障碍相关脂肪肝病 (MASLD) 流行病学的最新文献、其与心血管疾病 (CVD) 结果的相关性，以及评估非酒精性肝病命名法的更新疾病（NAFLD）。

最近的发现

诊断标准从 NAFLD 更新为 MASLD，减少了与饮酒和不良健康选择相关的耻辱感。它还揭示了心脏代谢危险因素在疾病病理生理学中的关键作用。随着心脏代谢危险因素人口负担的增加，预计未来 MASLD 的发病率和患病率将显着增加。 MASLD 也是发生 CVD 的一个潜在风险因素，应通过多学科团队的整体方法来解决。

概括

随着代谢性肝病的新命名法在全球范围内得到采用，需要更多的研究来调查之前针对 NAFLD 的试验结果的适用性。预计MASLD的流行将在全球范围内继续增加，因此迫切需要治疗方法来扭转这一趋势。